transmembrane protein 184AGenealiases: SDMG1 · SLC51C1
Q-omics provides the consensus-scored TMEM184A profile across patient tissues and cancer cell-line models. TMEM184A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TMEM184A is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, TMEM184A RNA expression shows 16,578 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, LUAD, and TGCT as cancer lineages where TMEM184A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM184A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM184A survival associations across molecular data types. TMEM184A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM184A RNA expression–survival associations across cancer types. High TMEM184A expression shows unfavorable associations in COAD, LUAD, KIRP, LGG and OV, but favorable associations in ACC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TMEM184A RNA expression.
This table summarizes TMEM184A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM184A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM184A shows higher tumor expression in LUAD, THCA, BLCA, LUSC, LIHC and UCEC. The LUAD box plot shows higher TMEM184A RNA expression in tumor versus normal tissue (log2 FC = +2.874, t-test p < 0.001).
This table shows molecular features associated with TMEM184A in patient tissues and cancer cell lines. In patient samples, TMEM184A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM184A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and URINARY_TRACT.
